Összefoglaló. Bevezetés: Mind a dializált, mind a veseátültetett betegek körében vezető haláloknak számít a cardiovascularis megbetegedés. E mögött főképp bal kamrai hypertrophia, volumenterheltség, következményes szívritmuszavar, szívbillentyű-elégtelenség, fokozott atherosclerosis állhat. Célkitűzés: Célunk a vesetranszplantáció hatásának vizsgálata a bal kamra pumpafunkciójára, a szívritmuszavarokat kiváltó és meghatározó tényezőkre és a vitiumokra nézve. Módszerek: A 2014. december 20. és 2018. június 21. közti időintervallumban, a Debreceni Egyetem Szervtranszplantációs Tanszékén felnőtt betegeken végzett veseátültetéseket vizsgáltuk retrospektív analízissel (n = 184). Vesetranszplantációt megelőzően, illetve azt követően 6 és 12 hónappal az echokardiográfiás, a laboratóriumi és a gyógyszeres terápiás értékeket tanulmányoztuk. A statisztikai elemzéseket khi-négyzet-próbával, Fisher-féle egzakt teszttel és Kruskal–Wallis-féle varianciaanalízissel (ANOVA) végeztük (szignifikancia: p<0,05). Eredmények: A bal kamra végsystolés tágassága az átültetés előtt 34,67 mm volt, míg a 6 hónapos eredmény 31,82 mm, a 12 hónapos 32,68 mm volt (p = 0,01). Átültetés előtt a stroke prevalenciája 7,87% volt, míg a beavatkozás után nem fordult elő szélütés (p<0,001). Transzplantáció hatására a bal pitvari átmérő (43,68 mm; 41,59 mm; 41,00 mm; p = 0,0417) és a káliumszint (4,98 mmol/l; 4,49 mmol/l; 4,49 mmol/l; p = 0,01) szignifikáns változást igazolt. Műtét előtt II. fokú mitralis regurgitatiót észleltünk 10,7%-nál, mely 4,3%-ra, majd 2,1%-ra csökkent (p = 0,03). Transzplantációt megelőzően a billentyűmeszesedés előfordulása diabetesesek között 45% (p = 0,20), 6 hónap múlva 46,7% (p = 0,018), 12 hónap múlva 60,0% (p = 0,024) volt. Következtetés: Transzplantáció után a bal pitvari átmérő, a végsystolés bal kamrai átmérő regrediál, csökken a pitvari ritmuszavarok kialakulásának gyakorisága. A mitralis regurgitatio közepesen súlyos fokainál szignifikáns javulást, a diabeteses populáción belül szignifikáns emelkedést tapasztaltunk a meszes billentyűk számát tekintve. Orv Hetil. 2021; 162(26): 1052–1062.
Summary. Introduction: Among the population suffering from end-stage renal failure and the population after kidney transplantation, the leading reason of death is cardiovascular triggered by left ventricular hypertrophy, volume overload, consecutive arrhythmias, valvular insufficiency and increased artherosclerosis. Objective: This study was aimed at examining the effect of kidney transplantation on pump function of the left ventricle, arrhythmic substrates and valvular heart diseases. Methods: At the Division of Organ Transplantation, University of Debrecen, we carried out a retrospective data analysis of adult patients (n = 184) who had kidney transplantation in the period between December 2014 and June 2018. Preoperatively and, then, postoperatively (at 6 and 12 months) we studied the echocardiographic parameters, the laboratory results. Statistical analyses were performed using the chi-square/Fisher’s exact test and Kruskal–Wallis analysis of variance (ANOVA) test. The results were regarded significant if p<0.05 was found. Results: Preoperatively the end-systolic diameter of the left ventricle was 34.67 mm, whereas 6 and 12 months later these values were 31.82 mm and 32.68 mm (p = 0.01). The prevalence of stroke was 7.87% preoperatively; there was no stroke detected postoperatively (p<0.001). The impact of transplantation on the left atrial diameter (43.68 mm; 41.59 mm; 41.00 mm; p = 0.04) and seral potassium level (4.98 mmol/l; 4.49 mmol/l; 4.49 mmol/l; p<0.01) showed significant improvement. Before transplantation, grade 2 mitral regurgitation was observed in 10.7% of the patients, whereas it reduced to 4.3%, then to 2.1% 6 and 12 months postoperatively (p = 0.03). Preoperative valvular calcification was detected in 45% of the diabetic study population (p = 0.20), 6 and 12 months later, in 46.7% (p = 0.018) and 60.0% (p = 0.024). Conclusion: After transplantation, the left atrial and the end-systolic diameter of the left ventricle regrediated, decreasing the frequency of arrhythmic episodes. The number of the middle grade mitral valve regurgitation decreased and the calcification among diabetic population increased significantly. Orv Hetil. 2021; 162(26): 1052–1062.
Kelly DM, Anders HJ, Bello AK, et al. Global Kidney Health Atlas: A report by the International Society of Nephrology on the current state of organization and structures for kidney care across the globe. International Society of Nephrology. 2021; 11(2): 106–108.
GBD 2015 Mortality and Causes of Death Collaborators, Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459–1544. [Erratum: Lancet 2017; 389: e1.]
Olechnowicz-Tietz S, Gluba A, Paradowska A, et al. The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol. 2013; 45: 1605–1612.
Kramer A, Pippias M, Noordzij M, at al. The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clin Kidney J. 2018; 11: 108–122.
Lam NN, Kim SJ, Knoll GA, et al. The risk of cardiovascular disease is not increasing over time despite aging and higher comorbidity burden of kidney transplant recipients. Transplantation 2017; 101: 588–596.
Késői I, Sági B, Vas T, et al. Cardiorenal syndromes. [Cardiorenalis szindrómak.] Orv Hetil. 2011; 152: 1520–1527. [Hungarian]
Abbott KC, Hshieh P, Cruess D, et al. Hospitalized valvular heart disease in patients on renal transplant waiting list: incidence, clinical correlates and outcomes. Clin Nephrol. 2003; 59: 79–87.
Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol. 2008; 102: 1131–1135.
P. Szabó R, Varga I, Balla J, et al. Cardiovascular screening and management among kidney transplant candidates in Hungary. Transplant Proc. 2015; 47: 2192–2195.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341: 1725–1730.
McGregor E, Jardine AG, Murray LS, et al. Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant. 1998; 13: 1499–1505.
Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999; 34: 125–134.
Ferreira SR, Moisés VA, Tavares A, et al. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation 2002; 74: 1580–1587.
Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019; 34: 760–773.
Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015; 28: 10–21.
Kocyigit I, Unal A, Elcik D, et al. Association between cardiac valvular calcification and serum fetuin-A levels in renal transplant recipients. Transplant Proc. 2015; 47: 1398–1401.
Sharma A, Gilbertson DT, Herzog CA. Survival of kidney transplantation patients in the United States after cardiac valve replacement. Circulation 2010; 121: 2733–2739.
Fox H, Büttner S, Hemmann K, et al. Transcatheter aortic valve implantation improves outcome compared to open-heart surgery in kidney transplant recipients requiring aortic valve replacement. J Cardiol. 2013; 61: 423–427.
Al-Rashid F, Bienholz A, Hildebrandt HA, et al. Transfemoral transcatheter aortic valve implantation in patients with end-stage renal disease and kidney transplant recipients. Sci Rep. 2017; 7: 14397.
Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450–458.
Mosteller RD. Simplified calculation of body surface area. N Engl J Med. 1987; 317: 1098.
Kensinger C, Hernandez A, Bian A, et al. Longitudinal assessment of cardiac morphology and function following kidney transplantation. Clin Transplant. 2017; 31: e12864.
Regele F, Kainz A, Kammer M, et al. Regression of left atrial diameter after kidney transplantation is associated with prolonged survival: an observational study. Transpl Int. 2018; 31: 999–1007.
Paoletti E, De Nicola L, Gabbai FB, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol. 2016; 11: 271–279.
Malyala R, Rapi L, Nash MM, et al. Pre-transplant left ventricular geometry and major adverse cardiovascular events after kidney transplantation. Ann Transplant. 2019; 24: 100–107.